Daiichi-Sankyo’s Access Central offers comprehensive reimbursement and support services for patients who are prescribed Injectafer or Turalio (Table).
The Injectafer Savings Program helps eligible patients with out-of-pocket Injectafer prescription costs. Uninsured and cash-paying patients are not eligible for this program. To qualify for the program, a patient must:
Patients who are uninsured or commercially underinsured and need help paying for their Injectafer treatment may be eligible for the Injectafer Patient Assistance Program. To qualify, a patient must:
Patients experiencing a 5-day delay in getting their prescription may be eligible for the Turalio QuickStart Program. To be eligible, patients must:
Additional terms and conditions apply.
Qualifying patients may pay as little as $0 per prescription of Turalio, with a maximum benefit of $25,000 per calendar year. To qualify:
The Turalio Patient Assistance Program may provide Turalio at no cost for financially eligible patients who are uninsured or underinsured. Eligibility criteria may be met if the patient has been denied coverage, is uninsured, or is functionally uninsured (denied prior authorization, formulary exclusion).
Medicare enrollees may be eligible for the Turalio Patient Assistance Program if they are unable to meet their out-of-pocket costs for Turalio and meet the required income criteria. Additional terms and conditions apply.
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
Help us fix it! Report broken links here.
Report Broken Links
Submit